Moore Capital Management’s Myriad Genetics MYGN Stock Holding History

Moore Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08M	Sell	188,526 -29,872	-14%	-$136K	0.02%	473
2026 Q1	$983K	Buy	+218,398	New	+$1.14M	0.02%	373
2024 Q3	–	Sell	-60,000	Closed	-$1.47M	–	527
2024 Q2	$1.47M	Buy	+60,000	New	+$1.32M	0.03%	288
2015 Q2	–	Sell	-20,795	Closed	-$736K	–	485
2015 Q1	$736K	Buy	+20,795	New	+$744K	0.02%	370
2014 Q2	–	Sell	-87,902	Closed	-$3M	–	545
2014 Q1	$3M	Sell	87,902 -77,098	-47%	-$2.39M	0.06%	240
2013 Q4	$3.46M	Buy	+165,000	New	+$4.17M	0.05%	227

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Moore Capital Management's MYGN Position: Q2 2026 in Review

Moore Capital Management reduced its Myriad Genetics (MYGN) stake by 14% in Q2 2026, selling an estimated $136K and leaving 188,526 shares worth $1.08M. The position accounts for 0.02% of the portfolio, ranked #473.

Moore Capital Management first reported a position in MYGN in Q4 2013 and has held it in 6 quarters since. The position peaked at $3.46M in Q4 2013. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

Moore Capital Management held 188,526 shares of Myriad Genetics worth $1.08M as of Q2 2026.
Moore Capital Management sold 29,872 Myriad Genetics shares in Q2 2026, an estimated $136K.
Myriad Genetics made up 0.02% of Moore Capital Management's portfolio in Q2 2026, its #473 holding.
Moore Capital Management first reported a position in Myriad Genetics in Q4 2013 and has held it in 6 quarters since.
Moore Capital Management's Myriad Genetics position peaked at $3.46M in Q4 2013.
196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.